Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Small Cell Lung Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Patients who have completed 4 course of platinum/etoposide and thoracic radiotherapy of 45 Gy/30 fractions, 2 fractions per day non-progression after chemo-radiotherapy ECOG performance status 0-2 will be randomized to receive atezolizumab 1200 mg IV every 3 weeks in 12 months or standard of care (o...
Patients who have completed 4 course of platinum/etoposide and thoracic radiotherapy of 45 Gy/30 fractions, 2 fractions per day non-progression after chemo-radiotherapy ECOG performance status 0-2 will be randomized to receive atezolizumab 1200 mg IV every 3 weeks in 12 months or standard of care (observation).
Tracking Information
- NCT #
- NCT03540420
- Collaborators
- Helse Stavanger HF
- University Hospital of North Norway
- Alesund Hospital
- Vestre Viken Hospital Trust
- Kantonsspital Winterthur KSW
- Zuyderland Medisch Centrum
- Isala
- Freiburger Spital
- Klinik Hirslanden, Zurich
- University Hospital, Akershus
- Amphia Hospital
- Levanger Hospital
- University Hospital, Linkoeping
- Kantonsspital Graubünden
- Nordlandssykehuset HF
- Sahlgrenska University Hospital, Sweden
- Karolinska University Hospital
- Rigshospitalet, Denmark
- The Netherlands Cancer Institute
- Odense University Hospital
- Haukeland University Hospital
- Kristiansund Hospital
- Ôrebro University Hospital
- Gävle Hospital
- St. Antonius Hospital
- University Hospital, Basel, Switzerland
- Skane University Hospital
- National Cancer Institute, Lithuania
- Spital STS AG
- Volda Hospital
- Aalborg University Hospital
- Oslo University Hospital
- Erasmus Medical Center
- Sorlandet Hospital HF
- Kantonsspital Olten
- University Hospital Inselspital, Berne
- Ullevaal University Hospital
- Molde Hospital
- Cantonal Hospital of St. Gallen
- Helse Fonna
- St. Olavs Hospital
- Ente Ospedaliero Cantonale, Bellinzona
- Rijnstate Hospital
- Medisch Spectrum Twente
- Investigators
- Study Director: Torstein B Rø, MD, PhD Norwegian University of Science and Technology
Get Well Soon